Clearmind Medicine Inc. (CMND) Research
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
Market snapshot
- Symbol
- CMND
- Price
- $3.07
- Day change
- -2.23%
- Market cap
- $3.1M
- P/E ratio
- -0.12x
- 52-week range
- 2.1-524
- Sector
- Healthcare
- Industry
- Biotechnology
Peer companies
Recent insider activity
- HRT FINANCIAL LP — S-Sale (22139 shares) on 2026-06-16
- HRT FINANCIAL LP — S-Sale (3183 shares) on 2026-06-15
- HRT FINANCIAL LP — S-Sale (2102 shares) on 2026-06-12
- HRT FINANCIAL LP — P-Purchase (2159052 shares) on 2026-06-10
- HRT FINANCIAL LP — S-Sale (225191 shares) on 2026-06-11
Open Clearmind Medicine Inc. (CMND) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.